Literature DB >> 25936984

Improvement and decline in vision with gene therapy in childhood blindness.

Samuel G Jacobson1, Artur V Cideciyan, Alejandro J Roman, Alexander Sumaroka, Sharon B Schwartz, Elise Heon, William W Hauswirth.   

Abstract

Retinal gene therapy for Leber's congenital amaurosis, an autosomal recessive childhood blindness, has been widely considered to be safe and efficacious. Three years after therapy, improvement in vision was maintained, but the rate of loss of photoreceptors in the treated retina was the same as that in the untreated retina. Here we describe long-term follow-up data from three treated patients. Topographic maps of visual sensitivity in treated regions, nearly 6 years after therapy for two of the patients and 4.5 years after therapy for the third patient, indicate progressive diminution of the areas of improved vision. (Funded by the National Eye Institute; ClinicalTrials.gov number, NCT00481546.).

Entities:  

Mesh:

Year:  2015        PMID: 25936984      PMCID: PMC4450362          DOI: 10.1056/NEJMoa1412965

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  21 in total

1.  Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics.

Authors:  Artur V Cideciyan; Tomas S Aleman; Sanford L Boye; Sharon B Schwartz; Shalesh Kaushal; Alejandro J Roman; Ji-Jing Pang; Alexander Sumaroka; Elizabeth A M Windsor; James M Wilson; Terence R Flotte; Gerald A Fishman; Elise Heon; Edwin M Stone; Barry J Byrne; Samuel G Jacobson; William W Hauswirth
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-22       Impact factor: 11.205

2.  Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success.

Authors:  Samuel G Jacobson; Tomas S Aleman; Artur V Cideciyan; Alexander Sumaroka; Sharon B Schwartz; Elizabeth A M Windsor; Elias I Traboulsi; Elise Heon; Steven J Pittler; Ann H Milam; Albert M Maguire; Krzysztof Palczewski; Edwin M Stone; Jean Bennett
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-18       Impact factor: 11.205

3.  Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness.

Authors:  Gregory M Acland; Gustavo D Aguirre; Jean Bennett; Tomas S Aleman; Artur V Cideciyan; Jeannette Bennicelli; Nadine S Dejneka; Susan E Pearce-Kelling; Albert M Maguire; Krzysztof Palczewski; William W Hauswirth; Samuel G Jacobson
Journal:  Mol Ther       Date:  2005-10-14       Impact factor: 11.454

Review 4.  Animal models of retinal detachment and reattachment: identifying cellular events that may affect visual recovery.

Authors:  G P Lewis; D G Charteris; C S Sethi; S K Fisher
Journal:  Eye (Lond)       Date:  2002-07       Impact factor: 3.775

5.  Photoreceptor layer topography in children with leber congenital amaurosis caused by RPE65 mutations.

Authors:  Samuel G Jacobson; Artur V Cideciyan; Tomas S Aleman; Alexander Sumaroka; Elizabeth A M Windsor; Sharon B Schwartz; Elise Heon; Edwin M Stone
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-06-06       Impact factor: 4.799

6.  Effect of gene therapy on visual function in Leber's congenital amaurosis.

Authors:  James W B Bainbridge; Alexander J Smith; Susie S Barker; Scott Robbie; Robert Henderson; Kamaljit Balaggan; Ananth Viswanathan; Graham E Holder; Andrew Stockman; Nick Tyler; Simon Petersen-Jones; Shomi S Bhattacharya; Adrian J Thrasher; Fred W Fitzke; Barrie J Carter; Gary S Rubin; Anthony T Moore; Robin R Ali
Journal:  N Engl J Med       Date:  2008-04-27       Impact factor: 91.245

7.  Safety and efficacy of gene transfer for Leber's congenital amaurosis.

Authors:  Albert M Maguire; Francesca Simonelli; Eric A Pierce; Edward N Pugh; Federico Mingozzi; Jeannette Bennicelli; Sandro Banfi; Kathleen A Marshall; Francesco Testa; Enrico M Surace; Settimio Rossi; Arkady Lyubarsky; Valder R Arruda; Barbara Konkle; Edwin Stone; Junwei Sun; Jonathan Jacobs; Lou Dell'Osso; Richard Hertle; Jian-xing Ma; T Michael Redmond; Xiaosong Zhu; Bernd Hauck; Olga Zelenaia; Kenneth S Shindler; Maureen G Maguire; J Fraser Wright; Nicholas J Volpe; Jennifer Wellman McDonnell; Alberto Auricchio; Katherine A High; Jean Bennett
Journal:  N Engl J Med       Date:  2008-04-27       Impact factor: 91.245

Review 8.  Leber congenital amaurosis: genes, proteins and disease mechanisms.

Authors:  Anneke I den Hollander; Ronald Roepman; Robert K Koenekoop; Frans P M Cremers
Journal:  Prog Retin Eye Res       Date:  2008-06-01       Impact factor: 21.198

9.  Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year.

Authors:  Artur V Cideciyan; William W Hauswirth; Tomas S Aleman; Shalesh Kaushal; Sharon B Schwartz; Sanford L Boye; Elizabeth A M Windsor; Thomas J Conlon; Alexander Sumaroka; Ji-Jing Pang; Alejandro J Roman; Barry J Byrne; Samuel G Jacobson
Journal:  Hum Gene Ther       Date:  2009-09       Impact factor: 5.695

10.  Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial.

Authors:  William W Hauswirth; Tomas S Aleman; Shalesh Kaushal; Artur V Cideciyan; Sharon B Schwartz; Lili Wang; Thomas J Conlon; Sanford L Boye; Terence R Flotte; Barry J Byrne; Samuel G Jacobson
Journal:  Hum Gene Ther       Date:  2008-10       Impact factor: 5.695

View more
  132 in total

Review 1.  [Gene therapy as a treatment concept for inherited retinal diseases].

Authors:  J-S Bellingrath; M D Fischer
Journal:  Ophthalmologe       Date:  2015-09       Impact factor: 1.059

2.  Success against blindness encourages gene therapy researchers.

Authors:  Heidi Ledford
Journal:  Nature       Date:  2015-10-22       Impact factor: 49.962

3.  Highly Efficient Delivery of Adeno-Associated Viral Vectors to the Primate Retina.

Authors:  Shannon E Boye; John J Alexander; C Douglas Witherspoon; Sanford L Boye; James J Peterson; Mark E Clark; Kristen J Sandefer; Chris A Girkin; William W Hauswirth; Paul D Gamlin
Journal:  Hum Gene Ther       Date:  2016-08       Impact factor: 5.695

4.  Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.

Authors:  Stephen Russell; Jean Bennett; Jennifer A Wellman; Daniel C Chung; Zi-Fan Yu; Amy Tillman; Janet Wittes; Julie Pappas; Okan Elci; Sarah McCague; Dominique Cross; Kathleen A Marshall; Jean Walshire; Taylor L Kehoe; Hannah Reichert; Maria Davis; Leslie Raffini; Lindsey A George; F Parker Hudson; Laura Dingfield; Xiaosong Zhu; Julia A Haller; Elliott H Sohn; Vinit B Mahajan; Wanda Pfeifer; Michelle Weckmann; Chris Johnson; Dina Gewaily; Arlene Drack; Edwin Stone; Katie Wachtel; Francesca Simonelli; Bart P Leroy; J Fraser Wright; Katherine A High; Albert M Maguire
Journal:  Lancet       Date:  2017-07-14       Impact factor: 79.321

5.  Public biotech in 2014--the numbers.

Authors:  Chris Morrison; Riku Lähteenmäki
Journal:  Nat Biotechnol       Date:  2015-07       Impact factor: 54.908

6.  Gene therapy 'cure' for blindness wanes.

Authors:  Anna Azvolinsky
Journal:  Nat Biotechnol       Date:  2015-07       Impact factor: 54.908

7.  AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression.

Authors:  Kun Ding; Jikui Shen; Zibran Hafiz; Sean F Hackett; Raquel Lima E Silva; Mahmood Khan; Valeria E Lorenc; Daiqin Chen; Rishi Chadha; Minie Zhang; Sherri Van Everen; Nicholas Buss; Michele Fiscella; Olivier Danos; Peter A Campochiaro
Journal:  J Clin Invest       Date:  2019-08-13       Impact factor: 14.808

Review 8.  Persistent remodeling and neurodegeneration in late-stage retinal degeneration.

Authors:  Rebecca L Pfeiffer; Robert E Marc; Bryan William Jones
Journal:  Prog Retin Eye Res       Date:  2019-07-26       Impact factor: 21.198

Review 9.  Statement of the DOG, the RG, and the BVA on the therapeutic use of voretigene neparvovec (Luxturna™) in ophthalmology. English version : January 2019.

Authors: 
Journal:  Ophthalmologe       Date:  2020-01       Impact factor: 1.059

Review 10.  BEST1: the Best Target for Gene and Cell Therapies.

Authors:  Tingting Yang; Sally Justus; Yao Li; Stephen H Tsang
Journal:  Mol Ther       Date:  2015-09-21       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.